Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and Medicaid Services (CMS) that a final National Coverage Decision (NCD) for Provenge has been issued requiring Medicare contractors to cover Provenge for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
Additionally, Provenge is being issued a Q-code effective July 1, 2011, which allows for electronic submission of claims and is expected to accelerate time to payment for physicians.
Dendreon has committed itself to continue supporting programs to provide comprehensive assistance for eligible men seeking access to treatment with Provenge, including through grants to independent foundations and establishment of a patient assistance program for uninsured patients. Dendreon provides grants to independently run foundations providing qualifying patients with financial assistance for co-pays, co-insurance, and treatment-related travel costs.
The last two days were winning days for men with advanced prostate cancer.
Joel T. Nowak